Integrated Cardiac Safety Assessment Methodologies for Noncardiac Drugs in Discovery Development and Postmarketing Surveillance

Description

Integrated Cardiac Safety Assessment Methodologies for Noncardiac Drugs in Discovery Development and Postmarketing Surveillance The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug’s cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug’s life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, government officials, and students.